News
ROYAL CANIN®: Pets Need Proper Diet Post Neutering

Potential weight gain poses many underlying health risks
KUALA
LUMPUR, MALAYSIA – Media OutReach – 10 February 2021 – It
is crucial for the neutered pet cats to be fed a specific diet, and ROYAL
CANIN® FHN Sterilised — is catered to control the body weight of felines. It helps
to limit the risk of excess weight gain as it contains moderate levels of fat
and adequate daily rations.
According
to Dr Dylan Choy, Royal Canin Malaysia Scientific Communication Manager,
neutering your pets is important to keep control of the stray population in
your neighbourhood, and also for health benefits.
“Numerous
studies have proven that neutered cats are healthier and have a longer lifespan
as neutering cats helps prevent uterine infections and mammary gland tumours
while also decreasing the risk of testicular cancer and prostrate problems in
male cats,” said Dr Dylan Choy.
Neutering
cats can also reduce the risk of contracting the Feline Immunodeficiency Virus
(FIV) which is spread through saliva and blood when they fight and bite each
other. Similarly, more lethal Feline Leukaemia Virus (FeLV) can also be
transmitted through saliva or nasal secretions. The retrovirus, if not fought
off by your furkid’s immune system may result in diseases that could be fatal.
The
daily energy requirements reduce post-neutering and the lack of proper
nutrition or control could lead to obesity in felines that in turn, could
result in other issues like joint problems, urinary tract issues and an
increased risk of contracting diabetes. There is also a risk of digestive
problems due to inactivity and excessive self-grooming habits that are usually
found in sedentary or indoor cats.
“The
biggest complication that may arise is the health risks stemming from the
potential weight gain of your neutered cat. It is normal for a cat’s food
intake to increase within 48 hours of the sterilisation process,” she
adds.
ROYAL
CANIN® FHN Sterilised supports a healthy urinary system by providing an
adequate mineral balance thus minimising the risk of developing urinary stones.
Besides, ROYAL CANIN® FHN Sterilised is packed with high-protein which is
essential to maintain muscle mass. It also contains L-Carnitine which is
involved in fat metabolism.
Get
your preferred pack of ROYAL CANIN® FHN Sterilised at Royal Canin Trusted
Partner pet stores (https://www.royalcanin.com/my/where-to-buy) and on Royal
Canin Official Store found on Shopee (https://shopee.com.my/royalcanin.os) and
Lazada (https://www.lazada.com.my/royal-canin/). For more information, log on
to
News
Hong Kong Productivity Council and Hong Kong Computer Society Sign Pact to Enhance the Adoption of Emerging Technologies in Hong Kong

HONG KONG SAR – Media OutReach – 22 February 2021 – The Hong Kong Productivity Council (HKPC) and the Hong Kong Computer Society (HKCS) today signed a Memorandum of Understanding (MoU) to form a strategic partnership in driving the adoption of emerging technologies in Hong Kong.
Mr Mohamed Butt, Executive Director of HKPC (left), and Ir Dr Ted Suen, MH, President of HKCS, sign a Memorandum of Understanding in which HKPC and HKCS will form a strategic partnership in driving the adoption of emerging technologies in Hong Kong.
Under the two-year arrangement, HKPC and HKCS will collaborate on talent development, education and promotion for emerging technologies to support the industry demand with focus in the areas of 5G, artificial intelligence (AI), cloud computing, cyber security, data analytics, Internet of Things (IoT) and robotics. This collaboration also signals HKPC’s relentless drive to invest in and build technologies that matter for Hong Kong in areas including reindustrialisation, SME and start-up support, intelligent manufacturing, digitalisation and cyber security, FutureSkills and smart and green living. HKCS members and local IT professionals will definitely benefit from this collaboration.
Mr Mohamed Butt, Executive Director of HKPC, said, “Being the expert of Industry 4.0 and Enterprise 4.0, HKPC has a team of technical professionals with a good grasp of technology research and development and advanced technologies such as IoT, big data analytics, AI and robotics, smart manufacturing. Our professional knowledge and acute technology sense will certainly help achieve more effective use of this collaboration.”
Dr Ted Suen, MH, President of HKCS, said, “With the continuous expansion of emerging technologies such as 5G and AI, coupled with the impact of the COVID-19 pandemic, many enterprises need to accelerate digital transformation to meet actual situation needs. The signing of the MoU will further strengthen collaboration between both parties, especially in the promotion of the application of emerging technologies.”
HKPC will set out a framework with HKCS to promote technology training courses organised by HKPC to its members and offer its government funding advisory support through SME ReachOut. HKCS, in turn, will recognise the relevant technology training courses offered by HKPC as continuing professional development activities and share the insights of the skills demand from the industries for HKPC to design training courses. Both sides also pledge to jointly promote and co-organise events related to emerging technologies such as seminars, webinars and workshops.
To mark the launch of the new collaboration, a webinar was held today with HKPC and HKCS experts sharing their insights of the Agile approach, intelligent automations and how they could enable enterprises to accelerate digital transformation.
About Hong Kong Productivity Council
The Hong Kong Productivity Council (HKPC) is a multi-disciplinary organisation established by statute in 1967, to promote productivity excellence through integrated advanced technologies and innovative service offerings to support Hong Kong enterprises. HKPC is the champion and expert in facilitating Hong Kong’s reindustrialisation empowered by i4.0 and e4.0 — focusing on R&D, IoT, big data analytics, AI and Robotic technology development, digital manufacturing, etc., to help enterprises and industries upgrade their business performance, lower operating costs, increase productivity and enhance competitiveness.
The Council is a trusted partner with comprehensive innovative solutions for Hong Kong industries and enterprises, enabling them to achieve resources and productivity utilisation, effectiveness and cost reduction, and enhanced competitiveness in both local and international marketplace. It offers SMEs and startups immediate and timely assistance in coping with the ever-changing business environment, accompanying them on their innovation and transformation journey.
In addition, HKPC partners and collaborates with local industries and enterprises to develop applied technology solutions for value creation. It also benefits a variety of sectors through product innovation and technology transfer, with commercialisation of multiple market-driven patents and technologies, bringing enormous opportunities abound for licensing and technology transfer, both locally and internationally.
For more information, please visit HKPC’s website: www.hkpc.org.
About Hong Kong Computer Society
Founded in 1970, the Hong Kong Computer Society (HKCS) is a recognised non-profit professional organisation focused on developing Hong Kong’s Information Technology (IT) profession and industry. Their members come from a broad spectrum of Hong Kong’s IT community, from corporations to like-minded individuals, all coming together to raise the profile and standards of the IT profession and industry. As a well-established IT professional body, the Society is committed to professional and industry development as well as community services to ensure the IT sector continues to make a positive impact on peoples’ lives with three main goals, namely, 1) talent cultivation and professional development, 2) industry development and collaboration, and 3) the effective use of IT in our community.
For more details, please visit HKCS’s website http://www.hkcs.org.hk
News
Citi Plus® Official Launch Ceremony

HONG KONG SAR – Media OutReach – 22 February 2021
Photo 1
Mr Lawrence Lam, Consumer Business Manager of Citibank Hong Kong, introduces saving, investment and spending services of Citi Plus® that are designed to suit needs of the younger generation.
Photo 2
Mr Lawrence Lam, Consumer Business Manager of Citibank Hong Kong, and Ms Josephine Lee, Head of Retail Bank at Citibank Hong Kong, unveil Citi Plus® at the official launch ceremony.
Photo 3
Mr Lawrence Lam, Consumer Business Manager (third from left) and Ms Josephine Lee, Head of Retail Bank of Citibank Hong Kong (forth from left), exchange wealth management tips with singer Hins Cheung (fifth from left), Jason Chan (first from left), artist Elva Ni (second from left), and athlete Cecilia Yeung (sixth from left), and talk about how Citi Plus’ features can address clients’ pain points, supporting them to achieve investment goals.
News
Voluntary Announcement: IND Approval Received for A Phase III Clinical Trial of OT-101 in the United States

HONG KONG SAR – Media OutReach – 22 February 2021 – This announcement is made by Ocumension Therapeutics (the “Company“, together with its subsidiaries, the “Group“) on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.
The board of directors of the Company (the “Board“) is pleased to announce that an investigational new drug (“IND“) approval for initiating a multi-regional phase III clinical trial (the “Phase III MRCT“) in the United States for OT-101, a self developed product of the Group, has been received from the United States Food and Drug Administration in February 2021. The Company plans to file IND applications with the regulatory authorities in both China and Europe Union in 2021 and initiate the Phase III MRCT of OT-101 in these regions accordingly.
OT-101 is a low-concentration atropine 0.01% eye drop developed by the Group to retard, or slow down, the progression of myopia in children and adolescents. The instability of low-concentration atropine solutions has long been a technical barrier for its commercialization. The Group developed a storage and delivery system to address low-concentration atropine solution’s instability, and also conducted several rounds of tests on the system’s reliability, closure integrity and sterility conditions.
Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will ultimately commercialize OT-101 successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.
By order of the Board of
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Executive Director
As of the date of this announcement, the Board comprises Dr. Lian Yong CHEN, Mr. Ye LIU, Dr. Zhaopeng HU and Dr. Wei LI as executive directors, Mr. Yanling CAO and Mr. Lefei SUN as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Lianming HE, and Mr. Yiran HUANG as independent non-executive directors.
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.